The rise of Viagra initially fueled a boom for pharma, but recent shifts present a murky outlook for investors. Generic versions are reducing profits, and continued litigation add further risk to the equation. While https://umarchqw670608.blogchaat.com/41464238/sildenafil-and-big-pharma-a-risky-play